Onderneming Aerie Pharmaceuticals, Inc.
Aandelen
AERI
US00771V1089
Farmaceutische producten
Vakgebied
Aantal werknemers: 376
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Endicott
CEO | Chief Executive Officer | 58 | 21-11-22 |
Andrew Allen
CMP | Compliance Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 01-03-22 | |
Chief Tech/Sci/R&D Officer | - | 03-02-20 | |
David Biddell
PRN | Corporate Officer/Principal | - | - |
Leon J. Atencia
PRN | Corporate Officer/Principal | - | 15-07-21 |
Evan Hockman
SAM | Sales & Marketing | - | - |
Wanda Francies
HRO | Human Resources Officer | - | - |
Kenji Aso
PRN | Corporate Officer/Principal | - | - |
Gerry McKenzie
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ian Bell
BRD | Director/Board Member | 54 | 21-11-22 |
Chairman | 57 | 21-11-22 | |
Jonathan Balch
BRD | Director/Board Member | - | 21-11-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 49 417 407 | 49 245 119 ( 99,65 %) | 0 | 99,65 % |
Bedrijfsgegevens
Aerie Pharmaceuticals, Inc.
6201 South Freeway
76134, Forth Worth
+919 237 5300
http://www.aeriepharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |